Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $17.3 million.

  • Amicus Therapeutics' Profit After Tax rose 35718.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 8656.87%. This contributed to the annual value of -$56.1 million for FY2024, which is 6298.69% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Profit After Tax stood at $17.3 million, which was up 35718.53% from -$24.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Profit After Tax ranged from a high of $17.3 million in Q3 2025 and a low of -$85.3 million during Q1 2022
  • For the 5-year period, Amicus Therapeutics' Profit After Tax averaged around -$38.1 million, with its median value being -$43.2 million (2023).
  • Data for Amicus Therapeutics' Profit After Tax shows a peak YoY increase of 35718.53% (in 2025) and a maximum YoY decrease of 5557.11% (in 2025) over the last 5 years.
  • Amicus Therapeutics' Profit After Tax (Quarter) stood at -$83.3 million in 2021, then surged by 32.92% to -$55.9 million in 2022, then soared by 39.42% to -$33.8 million in 2023, then skyrocketed by 143.55% to $14.7 million in 2024, then grew by 17.42% to $17.3 million in 2025.
  • Its Profit After Tax stands at $17.3 million for Q3 2025, versus -$24.4 million for Q2 2025 and -$21.7 million for Q1 2025.